Becton Dickinson & Co.
Moat Score — Becton Dickinson & Co.
Total Moat Score
15 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | BD carries a well-established brand and regulatory approvals across thousands of SKUs, but much of its medication-delivery portfolio (needles, syringes) is genericizable with limited patent protection. Its interventional device lines carry stronger IP and clinical differentiation. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 3 / 5 | Decades of manufacturing scale in high-volume consumables give BD real unit-cost advantages over smaller rivals, though commodity categories face margin pressure from lower-cost competitors like generic needle/syringe makers. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 2 / 5 | Hospital group purchasing organizations and increasing commodity competition in basic consumables constrain pricing, though differentiated interventional and connected-device products command premium pricing. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | BD's business is manufacturing and distribution of physical medical devices; there is no meaningful network effect where the product becomes more valuable as more customers use it. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 4 / 5 | BD's installed base of infusion pumps and medication-management systems creates high switching costs, since replacing platforms requires retraining, revalidation, and new capital investment across a health system. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 3 / 5 | The medical-consumables and interventional-device markets are large and mature with a handful of established suppliers, but not so tightly balanced that new entrants are structurally deterred outside of regulatory barriers. |